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Abstract. Raman and infrared spectroscopy are optical spectroscopic techniques that use light scattering (Raman) and light
absorption (infrared) to probe the vibrational energy levels of molecules in tissue samples. Using these techniques, one can gain
an insight into the biochemical composition of cells and tissues by looking at the spectra produced and comparing them with
spectra obtained from standards such as proteins, nucleic acids, lipids and carbohydrates. As a result of optical spectroscopy
being able to measure these biochemical changes, diagnosis of cancer could take place faster than current diagnostic methods,
assisting and offering pathologists and cytologists a novel technology in cancer screening and diagnosis.
The purpose of this study is to use both spectroscopic techniques, in combination with multivariate statistical analysis tools, to
analyze some of the major biochemical and morphological changes taking place during carcinogenesis and metastasis in lymph
nodes and to develop a predictive model to correctly differentiate cancerous from benign lymph nodes taken from oesophageal
cancer patients.
The results of this study showed that Raman and infrared spectroscopy managed to correctly differentiate between cancerous
and benign oesophageal lymph nodes with a training performance greater than 94% using principal component analysis (PCA)-
fed linear discriminant analysis (LDA). Cancerous nodes had higher nucleic acid but lower lipid and carbohydrate content
compared to benign nodes which is indicative of increased cell proliferation and loss of differentiation.
With better understanding of the molecular mechanisms of carcinogenesis and metastasis together with use of multivariate
statistical analysis tools, these spectroscopic studies will provide a platform for future development of real-time (in surgery)
non-invasive diagnostic tools in medical research.
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1. Introduction
Cancer is a disease of the cells in the body where normal cell division has become uncontrolled and
unregulated through mutations in the cell’s DNA which leads to the production of a growth or lump of
tissue made up of these abnormal tumours cells. These tumour growths can become malignant (cancers)
gaining the ability to spread to nearby tissues and organs by invasion and metastasis. Cancer cells from
this growth may also break off from the primary tumour and invade the bloodstream or lymphatic vessels
to be carried to other parts of the body to multiply and form secondary tumours (metastases). The most
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common places for metastases, in addition to lymph nodes, are the adrenals, lungs, liver, brain and
bones [1]. The progression of a primary tumour to formation of a secondary tumour or metastasis carries
a worse prognosis and can be associated with a poor survival in most cancers [2,3]. The first site of
metastasis is usually the lymph nodes near the primary tumour called regional lymph nodes which makes
lymph nodes sampling and pathological examination important in assessing whether a primary tumour
has spread or has the potential to spread to distant sites to develop secondary tumours [4]. However,
current conventional lymph node histopathology staging and grading relies on a morphological analysis
by a pathologist and is subject to significant inter- and intra-observer variation [5]. There is a need for a
more sensitive and objective tool in lymph node diagnostics.
Raman and infrared spectroscopy are optical techniques that can be used to interrogate biological
tissues in order to understand the changes in the molecular constituents that are associated with cancer
progression from normal to malignant during carcinogenesis. These spectroscopic techniques have the
ability to provide detailed biochemical information since the spectrum obtained from cellular and tissue
measurements are intrinsic molecular fingerprint of the sample that reveals information about the DNA,
carbohydrate, protein and lipid content [6].
Raman spectroscopy is based on the inelastic scattering of photons by molecular bond vibrations
where the shift towards lower frequencies is measured as a small portion of the incident photons are
scattered by interaction with the bonds of molecules in the tissue. Infrared spectroscopy is a form of
absorption spectroscopy that detects these molecular bond vibrations within a sample via interrogation of
the sample using the mid-infrared region of light where the loss of energy or frequency from the incident
light is measured as it is absorbed by the molecules in the tissue. Raman and infrared spectroscopy can
be used together to obtain more biochemical information from the tissue since certain chemical bonds
are more sensitive in Raman than in infrared and vice-versa. For example, hydroxyl stretching, amine
stretching and carbonyl groups are usually stronger in FTIR while carbon–carbon double and triple
bonds and aromatic symmetrical vibrations are stronger in Raman.
Raman spectroscopic studies have been used to differentiate between different pathologies in a number
of cancer types including colon [7,8], oesophageal [9], brain [10], skin [11] and laryngeal [12] cancers
as well as lymph nodes [13]. Smith et al. [13] used axillary lymph nodes from breast cancer patients, to
demonstrate a correct classification for cancerous nodes with 81% sensitivity and 97% specificity using
Raman spectroscopy.
Infrared spectroscopic studies have been used to differentiate between different pathologies in
skin [14], cervical [15], colorectal [16], leukaemia [17] and prostate cancers [18].
This study has been set up to use both spectroscopic techniques, in combination with multivariate
statistical analysis tools, to analyse some of the major biochemical and morphological changes taking
place during carcinogenesis and metastasis in lymph nodes and to develop a predictive model to correctly
differentiate cancerous from benign lymph nodes taken from oesophageal cancer patients.
2. Materials and methods
2.1. Tissue preparation for spectroscopic analysis and histopathology
Lymph node samples were selected and removed during oesophagectomies to remove the primary
tumours from patients, who consented to donation of lymph nodes for spectroscopic studies. Lymph
node samples were cut in half, where one half was placed in formalin and sent for routine histopathology
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(paraffin-embedded sectioning and standard tissue processing) while the other half was snap-frozen in
liquid nitrogen and stored in −80◦C freezers for spectroscopic analysis.
Frozen unstained sections were prepared of 15 µm thickness using a cold cryotome and were mounted
on a calcium fluoride (CaF2) slide. Prior to spectroscopic measurements, these frozen sections were
allowed to defrost and air-dry for at least 45 min.
2.2. Raman and infrared microspectroscopy
Raman spectra were collected using a Renishaw® System 1000 Raman microspectrometer consisting
of a spectrometer coupled to a diode laser (laser output of 350 mW and tuned to 830 nm to reduce
autofluorescence from tissue), a Leica® microscope with a condenser, a Prior® electronic stage, a video
viewer and a desktop computer with customised Grams® software and WiRE (Windows based Raman
Environment) software (version 1.3.15). Twenty to thirty point spectra were measured at 20 seconds, in a
single accumulation with an 80× objective from each tissue section. Image maps (20 s, 1 accumulation,
100 µm steps) were performed on the tissue sections for morphological comparison with haematoxylin
and eosin stained sections as well as spectroscopic comparison with FTIR hyper-spectral maps.
Infrared spectra were collected using a Perkin Elmer® Spotlight 300 Fourier transform infrared (FTIR)
spectroscopy system in transmission mode. The system has a liquid nitrogen cooled linear MCT array
detector, a video camera attached to a microscope to view optical images and a programmable comput-
erized x–y–z stage. An aperture size of 30× 30 µm was used to collect 20–30 point spectra (64 sample-
background rationed co-scans) within the wave number range 720–4000 cm−1 with a spectral resolution
of 4 cm−1. Image maps (64 sample-background rationed co-scans, aperture size of 100 × 100 µm)
within the wave number range 720–4000 cm−1 with a spectral resolution of 4 cm−1 were performed on
the tissue sections for morphological comparison with haematoxylin and eosin stained sections as well
as spectroscopic comparison with Raman hyper-spectral maps.
2.3. Data processing and statistical analysis
All data analysis was performed using Matlab 7® software.
2.3.1. Point spectra
Infrared point and map spectra were converted to absorbance using: (log(max(transmittance)) −
log(transmittance)), where transmittance = Iout/Iin.
Raman spectra were energy sensitivity-corrected using the green glass calibration spectrum and inter-
polated to 1 point per wavenumber.
Both Raman and infrared spectra were smoothed using 2nd order Savitzky–Golay filter to remove
short term variations or noise in the spectral dataset, area normalized, for correction of uniform intensity
changes by removing sources of systematic variation (e.g. differing amounts and thickness of sample)
between spectra.
Cancerous and benign mean spectra were generated from all cancerous point spectra and spectra from
all benign point spectra.
2.3.2. Map spectra
Raman and infrared map spectra were converted and loaded into Matlab to generate a 3D hyper-
spectral matrix for each section and then principal component analysis (PCA) was performed to generate
PCA pseudo colour maps. Pixel correction, using in-house scripts, was then performed on the Raman
PCA score maps to remove remaining cosmic rays and saturated spectra.
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Regions of interest were identified using the H&E stained section and corresponding features were
identified by anatomical landmarks on the unstained tissue sections. These regions were identified and
selected on the pseudo colour maps in order to generate a spectral dataset for each tissue section to
represent the lymph node’s overall tissue pathology spectra.
This combined spectral dataset was then normalized, mean-centred (by calculating the average spec-
trum of the data set and subtracting that average from each spectrum) and inputted into a PCA-fed linear
discriminant analysis (LDA) algorithm in order to assess the training performance for each spectroscopic
type in distinguishing the different pathology types (i.e. benign or cancerous).
3. Results
In total, 78,624 spectra were collected from the 20 lymph node tissue sections (11 cancerous and
9 non-cancerous nodes confirmed by histopathology).
Analysis of the mean pathology spectra for benign and cancerous (as illustrated in Fig. 1) show there
Fig. 1. (A) Raman mean spectra from benign (non-cancerous) and cancerous lymph nodes; (B) infrared mean spectra from
benign (non-cancerous) and cancerous lymph nodes.
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are biochemical differences between the spectra of the two pathology types for infrared and Raman
spectroscopy.
Benign lymph nodes have higher lipid (Raman: 1303 (CH), 1442 (CH2) [19,20]; infrared: 1745 (C=O
lipid ester), 1400 (COO−) [21]) and carbohydrate (Raman: 1084 (CC); infrared: 1165 (C–O), 1400
(COO−)) content compared to cancerous nodes demonstrating that lipids and carbohydrates are being
used as a fuel source during carcinogenesis to provide energy for rapid cell proliferation of tumor cells.
The increase of nucleic acid peaks (Raman: 724 (CH2), 1125 (CC)) in the Raman spectra indicates that
there is an increase in nuclear-to-cytoplasmic ratio and mitotic activity in cancerous tissue as observed
by Mahadevan-Jansen and Richards-Kortum in 1996 [23]. The asymmetrical (as PO−2 ) [1240] and sym-
metrical (sPO−2 ) [1089] [23] phosphodiester peaks seen in nucleic acid spectra are lower in cancerous
tissue however these phosphodiester peaks are also present in the spectra for phospholipids as well.
Therefore the higher levels of these peaks could be an indication of higher content of phospholipids,
rather than nucleic acids, in non-cancerous nodes.
After generating the absorbance maps for the infrared map spectra and average intensity maps for
Raman map spectra, comparison of these with the images from the H&E section showed that they can
provide visual separation of tissue type layers (e.g. cortex, medulla and capsule) seen in the H&E sec-
tions (as illustrated in Fig. 2).
Applying PCA-fed linear discriminant analysis to the spectral dataset resulted in a training perfor-
mance of 98% for infrared spectra and 94% for Raman spectra (as illustrated in Fig. 3). Cross-validation,
at this stage, was not attempted due to the small sample size.
4. Discussion
This initial study has shown that both infrared and Raman micro-spectroscopy when combined with
multivariate statistical analysis tools such as PCA-fed LDA analysis are able to discriminate non-
cancerous or benign from cancerous lymph node tissue with high performance results and demonstrates
that both methods have promising clinical and pathological applications. These training performances
are based on a small study with limited number of lymph nodes and once the remaining lymph nodes
(∼150), that have been collected for this project, are measured and included in the prediction model, bet-
ter performances and analysis can be performed and elucidation of further biochemical changes between
the pathology states can be identified.
After collecting and measuring additional lymph node spectra, a cross-validation-PCA-fed LDA
analysis can be performed to provide sensitivities and specificities for pathology prediction.
The analysis of the mean pathology spectra generated from the spectral data demonstrates it is possi-
ble to identify biochemical changes during carcinogenesis. By using Raman and infrared spectroscopy
combined, more biochemical information can be elicited from the tissue. However, as observed by others
[24–26], there are discrepancies in the literature regarding peak assignments and it has been observed
that most peaks have contributions from more than one biochemical component [27] resulting in bio-
chemical changes through peak assignment to be often speculative. Therefore multivariate statistical
applications, such as ordinary and non-negative least squares biochemical fitting, needs to be applied
so that biochemical analysis of the whole spectra at once can be made rather than use individual peak
assignments. Our group has already made attempts in biochemical analysis using non-negative least
squares fitting for prostate tissue [28], bladder tissue [29], aortic tissue [30] and oesophageal tissue [31].
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Fig. 2. Benign lymph node. (A) Image of hematoxylin and eosin (H&E) stained slide; (B) image of the unstained section slide,
(C) IR absorbance map (800–1800 cm−1 spectral range, 4 cm−1 spectral resolution, 25 µm spatial resolution, 64 coscans
(400 MB file)); (D) Raman intensity map (450–1850 cm−1 spectral range, 3.75 cm−1 spectral resolution, 55 µm spatial reso-
lution, 20 s per map point (100 MB file)).
(a) (b)
Fig. 3. (a) Histogram of linear discriminant scores for benign (non-cancerous) and cancerous lymph nodes for infrared spec-
troscopy; (b) histogram of linear discriminant scores for benign (non-cancerous) and cancerous lymph nodes for Raman spec-
troscopy (black: benign; grey: cancerous).
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